Supernus Inc SUPN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600
Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Trading Information
- Previous Close Price
- $28.75
- Day Range
- $28.67–29.66
- 52-Week Range
- $25.92–42.81
- Bid/Ask
- $29.18 / $30.05
- Shares Outstanding
- 207.72M
- Market Cap
- $1.72B
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 35.67
- Price/Sales
- 1.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 778
- Website
- https://www.supernus.com
Valuation
Metric | SUPN |
|---|---|
Price/Earnings (Normalized) | 35.67 |
Price/Book Value | 1.61 |
Price/Sales | 1.97 |
Price/Cash Flow | 10.31 |
Price/Earnings
SUPN
Financial Strength
Metric | SUPN |
|---|---|
Quick Ratio | 2.01 |
Current Ratio | 2.49 |
Interest Coverage | −16.17 |
Quick Ratio
SUPN
Profitability
Metric | SUPN |
|---|---|
Return on Assets (Normalized) | 3.32% |
Return on Equity (Normalized) | 4.53% |
Return on Invested Capital (Normalized) | 3.94% |
Return on Assets
SUPN
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|Gk$r%?L | LOCK|PVF&m | $74B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|SWj!@LL% | LOCK|%>$W | $50B | |||
| Haleon PLC ADR HLN | LOCK|&M$!YMQ | LOCK|%y | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|%^$YC%z | LOCK|@q | $34B | |||
| Viatris Inc VTRS | LOCK|Y#v>?^G | LOCK|d@j | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|%& | LOCK|Nb> | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|hMpkvN | LOCK|SJK | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|x^$#B<> | LOCK|Q? | $5B | |||
| Perrigo Co PLC PRGO | LOCK|w#K^$rJ | LOCK|?RJ | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|LN#y?v | LOCK|f$Lh | $2B |
United States